Drug Trial Radar · NCT07219017
A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Oct 15, 2025
Primary completion
Dec 9, 2025
Study completion Dec 9, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to assess the mass balance of oral ABBV-1354 in healthy adult male participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-1354Drug
Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 32 days
- Number of Participants with Abnormal Change from Baseline in Vital Sign MeasurementsTime frame: Up to approximately 15 days
- Change From Baseline in Electrocardiograms (ECGs)Time frame: Up to approximately 15 days
- Number of Participants with Abnormal Change in Physical ExaminationsTime frame: Up to approximately 15 days
- Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to approximately 15 days
- Maximum observed concentration (Cmax) of ABBV-1354Time frame: Up to approximately 15 days
- Time to Cmax (peak time, Tmax) of ABBV-1354Time frame: Up to approximately 15 days
- Terminal phase elimination half-life (t1/2) of ABBV-1354Time frame: Up to approximately 15 days
- Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-1354Time frame: Up to approximately 15 days
- Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-1354Time frame: Up to approximately 15 days
- Amount of ABBV-1354 excreted in the urine over the sampling period (Aeu)Time frame: Up to approximately 15 days
- Percent of ABBV-1354 excreted in the urineTime frame: Up to approximately 15 days
- Amount of ABBV-1354 excreted in the feces over the sampling period (Aeu)Time frame: Up to approximately 15 days
- Percent of ABBV-1354 radioactivity excreted in the fecesTime frame: Up to approximately 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit Inc /ID# 277011
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.